FMP
NASDAQ
2.38 USD
-0.02 (-0.84%)
Mr. Daniel Anton de Boer
Healthcare
Biotechnology
https://www.proqr.com
NASDAQ
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and researc...
0001612940
NL0010872495
N71542109
Zernikedreef 9
31 88 166 7000
NL
156
Sep 18, 2014
0001612940
NASDAQ
Biotechnology
Healthcare
N71542109
NL0010872495
NL
2.38
0.19
314.72k
192.34M
-
1.11-3.29
-0.94
-
-
-
-
-6.26
-
https://www.proqr.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.